Dextrostat

Dextrostat is a prescription medication used primarily for the treatment of attention‑deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. The active ingredient is dextroamphetamine sulfate, a stimulant that modulates the neurotransmitters norepinephrine and dopamine in the brain. It is supplied in an extended‑release formulation that delivers a controlled release of the drug over several hours, allowing once‑daily dosing.

The drug is marketed by GlaxoSmithKline and was first approved by the United States Food and Drug Administration (FDA) in 1997. Dextrostat falls under Schedule III of the Controlled Substances Act, reflecting its potential for abuse and dependence. It is usually prescribed at a starting dose of 2.5 mg to 5 mg once daily, and the dose can be adjusted in increments of 5 mg until an optimal therapeutic response is achieved. Patients are monitored for cardiovascular effects, appetite changes, sleep disturbances, and potential psychiatric symptoms.

Common side effects include insomnia, decreased appetite, dry mouth, headache, and increased heart rate or blood pressure. Rare but serious adverse reactions may involve cardiovascular events, seizure activity, or severe allergic reactions. Dextrostat should not be used by patients with a history of significant coronary artery disease, uncontrolled hypertension, or certain other medical conditions, and it is contraindicated in patients with known hypersensitivity to amphetamines. When used as directed, however, Dextrostat can improve concentration, impulse control, and academic or occupational functioning in individuals with ADHD.